Table 5.
Clinical measures at baseline, 6, and 12 weeks: First episode psychosis sample.
| Scale and visit | CareLoop enhanced monitoring, mean (SD) | Management as usual, mean (SD) | Adjusted mean differencea | 95% CI | P value, 2 tailed | |
| PANSSb Total | ||||||
|
|
Baseline | 73.11 (18.16) | 75.00 (15.72) |
|
|
|
|
|
Weeks 6 | 72.06 (16.86) | 75.44 (18.77) | –2.84 | –8.81 to 3.12 | .34 |
|
|
Week 12 | 71.50 (14.31) | 70.11 (19.24) | 2.69 | –4.81 to 10.19 | .47 |
| PANSS Positive | ||||||
|
|
Baseline | 18.44 (6.66) | 17.16 (5.1) |
|
|
|
|
|
Weeks 6 | 18.24 (6.82) | 16.56 (5.79) | 2.67 | –2.48 to 3.01 | .84 |
|
|
Week 12 | 18.06 (5.86) | 16.06 (6.35) | 1.10 | –2.16 to 4.35 | .498 |
| PANSS Negative | ||||||
|
|
Baseline | 15.83 (4.48) | 17.95 (5.69) |
|
|
|
|
|
Weeks 6 | 16.76 (4.28) | 19.28 (5.04) | –1.03 | –3.01 to .94 | .30 |
|
|
Week 12 | 16.5 (3.73) | 18.06 (4.83) | –0.50 | –3.09 to 2.10 | .70 |
| PANSS General | ||||||
|
|
Baseline | 38.83 (10.17) | 39.84 (8.34) |
|
|
|
|
|
Weeks 6 | 37.06 (9.13) | 39.61 (10.32) | –2.32 | –5.85 to 1.23 | .19 |
|
|
Week 12 | 36.94 (8.91) | 36.11 (10.44) | 1.33 | –2.60 to 5.26 | .495 |
| ERSc Total | ||||||
|
|
Baseline | 85.83 (9.32) | 79.26 (8.84) |
|
|
|
|
|
Weeks 6 | 85 (9.52) | 78.94 (12.25) | 1.40 | –4.73 to 7.53 | .65 |
|
|
Week 12 | 86.72 (16.05) | 80.72 (7.43) | 1.63 | –6.25 to 9.50 | .68 |
| EQ5Dd Total | ||||||
|
|
Baseline | 9.5 (3.59) | 11.21 (4.60) |
|
|
|
|
|
Weeks 6 | 9.22 (4.25) | 10.42 (4.86) | 0.10 | –2.48 to 2.69 | .94 |
|
|
Week 12 | 8.06 (7.38) | 6.116 (5.17) | –1.40 | –5.72 to 2.02 | .51 |
| CDSe Total | ||||||
|
|
Baseline | 5.72 (5.21) | 7.68 (5.23) |
|
|
|
|
|
Weeks 6 | 5.29 (4.81) | 8.06 (6.00) | –1.36 | –0.98 to 3.69 | .25 |
|
|
Week 12 | 5.06 (4.41) | 6.83 (5.48) | –0.63 | –1.81 to 3.07 | .61 |
| GAFf | ||||||
|
|
Baseline | 56.94 (13.12) | 53.84 (12.30) |
|
|
|
|
|
Weeks 6 | 52.64 (14.52) | 51.56 (16.79) | –1.19 | –8.51 to 6.15 | .74 |
|
|
Week 12 | 54.11 (14.65) | 57.17 (10.78) | –5.09 | –12.38 to 2.20 | .17 |
aFollow-up differences adjusted for baseline scores.
bPANSS: Positive and Negative Syndrome Scale
cERS: Empowerment Rating Scale
dEQ5D: EuroQol-5D
eCDS: Calgary Depression Scale
fGAF: Global Assessment of Functioning